- Conditions
- Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis
- Interventions
- Rituximab, Placebo
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 29
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
- Interventions
- FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo
- Dietary Supplement
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Dermatomyositis, Adult Polymyositis, Inclusion Body Myositis, Myositis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 7
- States / cities
- Miami, Florida • Bethesda, Maryland • Research Triangle Park, North Carolina + 3 more
- Conditions
- Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
- Interventions
- Efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Orange, California + 15 more
- Conditions
- DERMATOMYOSITIS OR POLYMYOSITIS
- Interventions
- MEDI-545, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Stanford, California • Whittier, California + 11 more
- Conditions
- Polymyositis, Dermatomyositis
- Interventions
- Anifrolumab (blinded), Placebo, Anifrolumab (unblinded, open label)
- Combination Product · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Irvine, California • Aurora, Colorado + 38 more
- Conditions
- Idiopathic Inflammatory Myositis
- Interventions
- Daxdilimab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Dermatomyositis, Adult Type
- Interventions
- Apremilast 30mg
- Drug
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Dermatomyositis
- Interventions
- GLPG3667, Placebo
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Upland, California • Kendall, Florida + 5 more
- Conditions
- Dermatomyositis
- Interventions
- PF-06823859 low, Placebo Arm, PF-06823859 high
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 17 more
- Conditions
- Dermatomyositis, Polymyositis, Inclusion Body Myositis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1995
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Bethesda, Maryland • Research Triangle Park, North Carolina + 1 more
- Conditions
- Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis, Juvenile Polymyositis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 580 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2011
- U.S. locations
- 8
- States / cities
- Miami, Florida • Baltimore, Maryland • Bethesda, Maryland + 5 more
- Conditions
- Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
- Interventions
- Descartes-08
- Drug
- Lead sponsor
- Cartesian Therapeutics
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • St Louis, Missouri • Cincinnati, Ohio
- Conditions
- Dermatomyositis
- Interventions
- IMO-8400 Dose Group 1, IMO-8400 Dose Group 2, Placebo
- Drug
- Lead sponsor
- Idera Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 14 more
- Conditions
- Dermatomyositis, Myositis
- Interventions
- Empasiprubart IV, Placebo IV
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 9
- States / cities
- Oceanside, California • DeBary, Florida • Gainesville, Florida + 6 more
- Conditions
- Myositis, Dermatomyositis
- Interventions
- Deucravacitinb
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
- Interventions
- EFG PH20 SC, PBO
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more
- Conditions
- Dermatomyositis, Idiopathic Inflammatory Myopathies
- Interventions
- Sodium Thiosulfate
- Drug
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 7 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy, Overlap Myositis, Juvenile Myositis Above the Age of 18
- Interventions
- Abatacept subcutaneous, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Orange, California + 22 more
- Conditions
- Calcinosis
- Interventions
- Fractionated Carbon Dioxide (FCO2) Laser, Sodium thiosulfate
- Device · Drug
- Lead sponsor
- Alison Ehrlich
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Dermatomyositis
- Interventions
- human immunoglobulin G, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 15
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
- Conditions
- Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
- Interventions
- ALLO-329, Cyclophosphamide, Fludarabine
- Genetic · Drug
- Lead sponsor
- Allogene Therapeutics
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 11 more
- Conditions
- Dermatomyositis
- Interventions
- KYV-101
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 25 Years to 72 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Stanford, California
- Conditions
- Dermatomyositis, Dermatomyositis, Adult Type
- Interventions
- Brepocitinib
- Drug
- Lead sponsor
- Priovant Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona